Sanger’s Head of Cancer, Ageing and Somatic Mutation Programme honoured by EMBO

Dr Peter Campbell becomes an elected member of the European Molecular Biology Organization

Sanger’s Head of Cancer, Ageing and Somatic Mutation Programme honoured by EMBO

Dr Peter Campbell has been elected as a member of EMBO (European Molecular Biology Organization)
Dr Peter Campbell has been elected as a member of EMBO (European Molecular Biology Organization). Image credit: Wellcome Sanger Institute, Genome Research Limited

Today (14 May 2018) Dr Peter Campbell joins 61 fellow researchers from 24 countries in being elected to membership of the European Molecular Biology Organization (EMBO). EMBO was created to promote excellence in molecular life sciences in Europe and each year recognises new members on the basis of scientific excellence.

Election as an EMBO Member is a testament to the significant contribution made to science by a researcher. Its membership is comprised of more than 1,800 of the world's foremost researchers in fields ranging from molecular biology and plant sciences, to infectious diseases, cancer and immunology.

"I am honoured to be elected to EMBO. My work in cancer genomics to discover the underlying genetic roots of cancer is both built on, and applied to, molecular biology to unpick the interplay of biological pathways within cancer cells. For this reason, I am thrilled to be recognised by my peers in this way. Cancer is a multi-faceted condition that requires large-scale collaboration and innovation to study and this award is recognition of the talents and efforts of all those I have worked with over the years and I thank them. EMBO plays a valuable role in promoting scientific partnerships across countries to foster high-quality science and drive the next wave of discovery."

Dr Peter Campbell, Head of the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute

Dr Campbell has had a major influence on the field of cancer genomics, through his groundbreaking analyses of somatic mutations in tumours. His research has identified new genes involved in a range of leukaemias and bone cancers, and discovered key mechanisms that drive the development of certain tumours by causing catastrophic damage to the genome.

Peter has also pioneered the innovative use of technology and computation to advance the genomic study of cancer and enhance clinical practice. By applying cutting-edge techniques in DNA sequencing and cell biology, Dr Campbell has systematically defined the landscape of mutation in cancer genomes at the highest possible resolution, and demonstrated that mutational data can be used to guide patients’ treatments in acute myeloid leukaemia.

“I have worked alongside Peter for many years and his dedication to leading the development of new technologies, global collaborations, fundamental discoveries and translation for patient benefit is inspirational. His leadership of the Cancer programme at the Sanger Institute and within the International Cancer Genome Consortium is shaping the future of cancer research, diagnosis and treatment. His election is fully merited and I am delighted he has received this honour."

Professor Sir Mike Stratton, Director of the Sanger Institute

Founded in 1964 to serve, what was then, the emerging discipline of molecular biology, EMBO recognises and fosters talented scientists. It seeks to achieve the highest scientific standards and promote cross-border exchange and collaborative research.

The organization’s members are actively involved in the execution of the organization’s initiatives by serving on EMBO Council, Committees and Editorial Boards, by evaluating applications for EMBO funding, by mentoring young scientists and by providing suggestions and feedback on activities.

“EMBO Members are leading scientists working across all of the life sciences. They also strengthen the research community in Europe and beyond through their international collaborations and connections.”

Professor Maria Leptin, EMBO Director

Peter will be formally welcomed at the Members’ Meeting in Heidelberg between 24 and 26 October 2018.

Notes to Editors
Selected Websites
Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Pharmacogenomics and cancerStoriesPharmacogenomics and cancer
Pharmacogenomics is a specific kind of genetic testing that offers key advantages for doctors trying to choose the best drugs for their patients.

Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Mutant cells colonise our tissues over our lifetime

Scientists may need to rethink the role of some cancer genes in the light of sequencing normal tissues

Milestone reached in major developmental disorders project

Eight years after launch, the Deciphering Developmental Disorders project has identified 49 completely new disorders and provided diagnoses to 4,500 children with rare diseases

Genetics allows personalised disease predictions for chronic blood cancers

The approach could help doctors identify which patients may benefit from specific treatments or clinical trials